US.DHR · Danaher Corporation

{
  "risk": {
    "level": "Low",
    "reason": "risk management score >= 8/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.4375217542638357,
        "turnoverUsdM": 1222.9006380500002,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.8,
    "stopLevels": {
      "symbol": "US.DHR",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 191.3058,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 3,
        "macd_score": 3,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.7,
      "stop_loss_percent": 4.9,
      "take_profit_price": 218.0059,
      "target_multiplier": 2.2,
      "technical_strength": 2.35,
      "take_profit_percent": 8.4
    },
    "positionPoints": 1.8,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.7230615450521207,
    "stopLossPercent": 4.875043508527671,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 72.6,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 64.6,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 8
  },
  "market": {
    "ma20": 194.695,
    "ma50": 183.2274,
    "close": 201.11,
    "prevClose": 203.83,
    "avgVolume20": 4249738,
    "volumeRatio": 1.43,
    "changePercent": -1.33
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 8,
    "details": {
      "ret_5d": 0.004746203037570007,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 8,
      "vcp_bonus": 0,
      "vol_ratio": 1.4112982680089357,
      "ret_points": 4,
      "vol_points": 4,
      "range_ratio": 0.8295875188068158,
      "volat_points": 0,
      "day_range_pct": 0.02153050569340168,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 0,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 72.6,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.8,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 56,
        "contribution": 2.8
      },
      {
        "raw": 14,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 70,
        "contribution": 14
      },
      {
        "raw": 9.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 64,
        "contribution": 9.6
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 8,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 80,
        "contribution": 8
      },
      {
        "raw": 20.2,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 67.33,
        "contribution": 20.2
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 64.6,
    "details": [
      "基本面分析總分: 2.8/5分",
      "資金流分析總分: 14/20分",
      "市場環境分析總分: 9.6/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 8/10分",
      "技術信號分析總分: 20.2/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 2.8,
      "資金流": 14,
      "市場環境": 9.6,
      "情緒分析": 4,
      "技術信號": 20.2,
      "風險管理": 8
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.4,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0.4,
          "turnoverUsdM": 1222.9006380500002,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "良好",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 3.2,
          "obvPoints": 2.4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.DHR",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 1.8,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 18.77
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 716.11750425,
                "ma50": 719.0110022000002,
                "name": "QQQ",
                "close": 696.059998,
                "points": 0.4
              },
              "spy": {
                "ma20": 744.7885068500001,
                "ma50": 744.54560184,
                "name": "SPY",
                "close": 742.090027,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.4375217542638357,
          "atrPoints": 3,
          "cciPoints": 4,
          "vixPoints": 1.8,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 3,
              "sentimentScoreRaw": 0.9
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140957168,
                "url": "https://finnhub.io/api/news?id=b1383772ddecb80d86a0cd3aefcdf94254b6db530b6aa24a312aac5787222e26",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Diversified science and technology company Danaher (NYSE:DHR) will be reporting results this Tuesday before market hours. Here’s what you need to know.",
                "category": "company",
                "datetime": 1784524150,
                "headline": "Danaher (DHR) Q2 Earnings Report Preview: What To Look For"
              },
              {
                "id": 140930833,
                "url": "https://finnhub.io/api/news?id=f7f5d7bdf196729ba552af92a464ef85d6921b4b439e2d648be78749a5dd7417",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Leica Biosystems, part of Danaher, has entered a definitive agreement to acquire StatLab Medical Products. The deal expands Danaher's diagnostics and anatomical pathology offering and adds more consumables and instruments to its portfolio. This development is relevant for investors tracking NYSE:DHR, as it focuses attention on the diagnostics segment. Danaher, traded as NYSE:DHR, is leaning further into diagnostics through Leica Biosystems' planned acquisition of StatLab Medical Products...",
                "category": "company",
                "datetime": 1784286743,
                "headline": "Danaher (DHR) Is Expanding Diagnostics With A StatLab Medical Products Deal"
              },
              {
                "id": 140929128,
                "url": "https://finnhub.io/api/news?id=ce8d49c148b3b8c37755896a219d237007309e246076cb3470fb82f5561a494e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher stock presents a clear valuation tension right now, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while the earnings based multiples suggest the shares are already pricing in a premium. Over the past 5 years, Danaher shareholders have seen the stock decline about 18%, which frames the current valuation debate against a weaker long term return profile. Recent news around portfolio moves in diagnostics and pathology can support expectations...",
                "category": "company",
                "datetime": 1784264942,
                "headline": "Danaher (DHR) Stock May Trade At A Discount Despite Its 18% Five Year Decline"
              },
              {
                "id": 140928691,
                "url": "https://finnhub.io/api/news?id=0034d5256249c3c8762c2f9702eddef42e000a76b97af27dc4f1cd1837c2546a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher, which released its Q2 2026 results on 21 July, saw expectations firm up ahead of the report as analysts projected modest year-on-year growth in revenue and earnings, helped by solid bioprocessing demand, improved filtration activity, and contributions from the Masimo acquisition despite cost pressures and higher debt. Investors are focusing on how Masimo’s integration and continued strength in bioprocessing and diagnostics could offset weaker areas like Diagnostics and rising input,...",
                "category": "company",
                "datetime": 1784254452,
                "headline": "Can Masimo’s Integration and Bioprocessing Strength Reshape Danaher’s Long-Term Story (DHR)?"
              },
              {
                "id": 140922770,
                "url": "https://finnhub.io/api/news?id=6c2da72828565fe47d4f12d7054c87e5c4c0a990028256d5cfa749490a4ce677",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1784218204,
                "headline": "Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?"
              },
              {
                "id": 140921108,
                "url": "https://finnhub.io/api/news?id=3b7a3c592c254f9582eda27e64ea6f8fc5853218c696d9e9ed9fcfd98689c3bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Besides Wall Street's top-and-bottom-line estimates for Danaher (DHR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.",
                "category": "company",
                "datetime": 1784207703,
                "headline": "Countdown to Danaher (DHR) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS"
              },
              {
                "id": 140898283,
                "url": "https://finnhub.io/api/news?id=39537e6385a0d8bb861f77ea8b66cc195721e4d593c7fb9cbf265322e26f00f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1784037609,
                "headline": "Danaher (DHR) Reports Next Week: Wall Street Expects Earnings Growth"
              },
              {
                "id": 140855851,
                "url": "https://finnhub.io/api/news?id=b78669addd9952e167ffd9d6b31c6133d81abcc3fe4ed720c2df88269166eb12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Beckman Coulter Diagnostics, part of Danaher (DHR), has received CE Mark under IVDR for its Access p-Tau217 blood assay, drawing fresh attention to the stock’s diagnostics exposure and valuation. See our latest analysis for Danaher. Against this diagnostic milestone, Danaher’s share price has softened this year. The stock is at $190.77 with a year to date share price return down 17.2%, while the 1 year total shareholder return is down 4.37%. This suggests sentiment has cooled despite interest...",
                "category": "company",
                "datetime": 1783631754,
                "headline": "Danaher (DHR) Wins CE Mark For Access P Tau217 Assay, Is The Stock A Bargain?"
              }
            ],
            "raw_source": [
              {
                "id": 140963655,
                "url": "https://finnhub.io/api/news?id=8e8a9bc177421c2262200b6f5b61cb3b7f17f1eaaca89b5b57203bb3162d8613",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/20/Bullish-Posts-Strong-Earnings.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "DHR",
                "summary": "Earnings are back in focus on Tuesday, with a Benzinga-selected slate including Danaher Corp. (NYSE:DHR). Options pricing reveals traders are bracing for volatility, with Annaly Capital Management (NYSE:NLY) and The Charles Schwab Corp. (NYSE:SCHW) reporting. Both stocks have seen positive analyst ratings and are trading above their 200-day moving averages.",
                "category": "company",
                "datetime": 1784561377,
                "headline": "Danaher Could Swing Over $7 Billion in Value After Earnings"
              },
              {
                "id": 140960535,
                "url": "https://finnhub.io/api/news?id=4a0c9cdc7347cf4f089f87cb71009406c597f7cc3ce3edf6c054e79446110d73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Wall Street heads into a pivotal week with investors preparing for a flood of corporate earnings, major artificial intelligence announcements and lingering geopolitical tensions that have pushed oil prices above $90 a barrel. The spotlight will be on Wednesday's earnings from Alphabet Inc...",
                "category": "company",
                "datetime": 1784558760,
                "headline": "Week ahead: Wall Street gears up for volatility as Big Tech earnings kick into high gear"
              },
              {
                "id": 140959628,
                "url": "https://finnhub.io/api/news?id=a02e69e3e5e25c25f43ad23e6bf60542d3a84db9da3b59b69daa776dabca02dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.",
                "category": "company",
                "datetime": 1784554533,
                "headline": "3 Cash-Producing Stocks with Warning Signs"
              },
              {
                "id": 140960936,
                "url": "https://finnhub.io/api/news?id=2c6b8b58a31f7aa66f8aa3b6773013169c86931d70da3969996fe4c331038e24",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/20/Quarterly-Results-Sales-Profits-Earnings.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "DHR",
                "summary": "Earnings season takes center stage next week with options markets pricing in big post-results moves. Benzinga selected top stocks to watch.",
                "category": "company",
                "datetime": 1784543345,
                "headline": "Intel Could Swing $61.4 Billion in Value After Earnings This Week"
              },
              {
                "id": 140957168,
                "url": "https://finnhub.io/api/news?id=b1383772ddecb80d86a0cd3aefcdf94254b6db530b6aa24a312aac5787222e26",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Diversified science and technology company Danaher (NYSE:DHR) will be reporting results this Tuesday before market hours. Here’s what you need to know.",
                "category": "company",
                "datetime": 1784524150,
                "headline": "Danaher (DHR) Q2 Earnings Report Preview: What To Look For"
              },
              {
                "id": 140951393,
                "url": "https://finnhub.io/api/news?id=aa6674b923f5dd3997e414963f20d36f2a01175a7747127b41d946914efb4677",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DHR",
                "summary": "Dan Loeb’s Third Point 13F: portfolio slashed to $2.08B, big AMZN stake, exits like MSFT, new META/GOOGL buys.",
                "category": "company",
                "datetime": 1784450913,
                "headline": "Tracking Dan Loeb's Third Point Portfolio - Q1 2026 Update"
              },
              {
                "id": 140939163,
                "url": "https://finnhub.io/api/news?id=2b7e563ff687d8cc979d3783bccd33f2bf9feb60d528dbd963b372e93e4735fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "The healthcare giant's stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.",
                "category": "company",
                "datetime": 1784328964,
                "headline": "Abbott Just Showed Its Growth Engine Has More Than One Cylinder"
              },
              {
                "id": 140933104,
                "url": "https://finnhub.io/api/news?id=40e9d7002eab4004d0bb87377bc6eff91abe0004872c0056185cab071cebb894",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Interactive Brokers leads Zacks' featured research, with reports also spotlighting Danaher, S&P Global and Optical Cable's growth drivers and risks.",
                "category": "company",
                "datetime": 1784294700,
                "headline": "The Zacks Analyst Blog Highlights Interactive Brokers, Danaher, S&P Global and Optical Cable"
              },
              {
                "id": 140931563,
                "url": "https://finnhub.io/api/news?id=9a8cdb541c3ef9be788480458508c8b7afe3ea54b0f0964b1a39fcf2f3561dab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "This healthcare giant is forecasting a significant acceleration, but you are being asked to look past a slowdown in its biggest growth engine and other execution hurdles.",
                "category": "company",
                "datetime": 1784290654,
                "headline": "Can Abbott Stock Deliver on Its Second-Half Growth Promise?"
              },
              {
                "id": 140930833,
                "url": "https://finnhub.io/api/news?id=f7f5d7bdf196729ba552af92a464ef85d6921b4b439e2d648be78749a5dd7417",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Leica Biosystems, part of Danaher, has entered a definitive agreement to acquire StatLab Medical Products. The deal expands Danaher's diagnostics and anatomical pathology offering and adds more consumables and instruments to its portfolio. This development is relevant for investors tracking NYSE:DHR, as it focuses attention on the diagnostics segment. Danaher, traded as NYSE:DHR, is leaning further into diagnostics through Leica Biosystems' planned acquisition of StatLab Medical Products...",
                "category": "company",
                "datetime": 1784286743,
                "headline": "Danaher (DHR) Is Expanding Diagnostics With A StatLab Medical Products Deal"
              },
              {
                "id": 140929128,
                "url": "https://finnhub.io/api/news?id=ce8d49c148b3b8c37755896a219d237007309e246076cb3470fb82f5561a494e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher stock presents a clear valuation tension right now, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while the earnings based multiples suggest the shares are already pricing in a premium. Over the past 5 years, Danaher shareholders have seen the stock decline about 18%, which frames the current valuation debate against a weaker long term return profile. Recent news around portfolio moves in diagnostics and pathology can support expectations...",
                "category": "company",
                "datetime": 1784264942,
                "headline": "Danaher (DHR) Stock May Trade At A Discount Despite Its 18% Five Year Decline"
              },
              {
                "id": 140929857,
                "url": "https://finnhub.io/api/news?id=5af17e559239cdd6954f090d6fa62bc90457aa54e7e1e7839f252f9aac4683c5",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1150663437/image_1150663437.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DHR",
                "summary": "Read here for an update on Barron’s 2026 dividend “dogcatcher” picks—safer high-yield stocks, projected gains to 2027, and free-cash-flow red flags.",
                "category": "company",
                "datetime": 1784264407,
                "headline": "2 DiviDog Buys By Barron's Mid-Year Round Table Pros"
              },
              {
                "id": 140928691,
                "url": "https://finnhub.io/api/news?id=0034d5256249c3c8762c2f9702eddef42e000a76b97af27dc4f1cd1837c2546a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher, which released its Q2 2026 results on 21 July, saw expectations firm up ahead of the report as analysts projected modest year-on-year growth in revenue and earnings, helped by solid bioprocessing demand, improved filtration activity, and contributions from the Masimo acquisition despite cost pressures and higher debt. Investors are focusing on how Masimo’s integration and continued strength in bioprocessing and diagnostics could offset weaker areas like Diagnostics and rising input,...",
                "category": "company",
                "datetime": 1784254452,
                "headline": "Can Masimo’s Integration and Bioprocessing Strength Reshape Danaher’s Long-Term Story (DHR)?"
              },
              {
                "id": 140927426,
                "url": "https://finnhub.io/api/news?id=78f11e4d4ffab8459cdc11b68842883243b41924b7a0953459ff8b2a758f39e8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Interactive Brokers, Danaher and S&P Global lead today's featured research, highlighting key growth drivers, challenges and performance trends.",
                "category": "company",
                "datetime": 1784237940,
                "headline": "Top Research Reports for Interactive Brokers, Danaher & S&P Global"
              },
              {
                "id": 140922770,
                "url": "https://finnhub.io/api/news?id=6c2da72828565fe47d4f12d7054c87e5c4c0a990028256d5cfa749490a4ce677",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1784218204,
                "headline": "Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?"
              },
              {
                "id": 140922763,
                "url": "https://finnhub.io/api/news?id=dc4955263ecd30f9602dfc000f5bacd34f86464174631084d5e636d601f094f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "DHR heads into Q2 earnings with bioprocessing and diagnostics strength, but rising costs and debt could pressure profitability.",
                "category": "company",
                "datetime": 1784216760,
                "headline": "Danaher Gears Up to Post Q2 Earnings: Is a Beat in the Offing?"
              },
              {
                "id": 140921108,
                "url": "https://finnhub.io/api/news?id=3b7a3c592c254f9582eda27e64ea6f8fc5853218c696d9e9ed9fcfd98689c3bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Besides Wall Street's top-and-bottom-line estimates for Danaher (DHR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.",
                "category": "company",
                "datetime": 1784207703,
                "headline": "Countdown to Danaher (DHR) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS"
              },
              {
                "id": 140909800,
                "url": "https://finnhub.io/api/news?id=fde23244a666d8526def31168d9334bb114a0cf4495c7890ac2d19b31790af39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1784124016,
                "headline": "Earnings Preview: Icon PLC (ICLR) Q2 Earnings Expected to Decline"
              },
              {
                "id": 140903058,
                "url": "https://finnhub.io/api/news?id=1b9bb79e5447925160f2cf761525689933de4e75cf258ab6dbfb7d1244658cda",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "BOSTON & CHICAGO, July 14, 2026--Audax Private Equity and Linden Capital Partners Agree to Sell StatLab Medical Products to Leica Biosystems",
                "category": "company",
                "datetime": 1784064300,
                "headline": "Audax Private Equity and Linden Capital Partners Agree to Sell StatLab Medical Products to Leica Biosystems"
              },
              {
                "id": 140903059,
                "url": "https://finnhub.io/api/news?id=1e39d6420c0c67e38dbe2b616151d8ebdc6d16de155a5eb7a549963ffc19a939",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Leica Biosystems, an operating company of Danaher (the \"Company\"), and a global leader in anatomic pathology solutions advancing precision cancer diagnostics, announced today that the Company has entered into a definitive agreement to acquire privately held StatLab Medical Products (\"StatLab\"), a leading global developer and manufacturer of anatomical pathology products, from Linden Capital Partners and Audax Private Equity. Following the closing, StatLab will become part of Leica Biosystems.",
                "category": "company",
                "datetime": 1784061000,
                "headline": "Leica Biosystems to Acquire StatLab"
              },
              {
                "id": 140903060,
                "url": "https://finnhub.io/api/news?id=fe60382848891c7ac10f46b825b984ecef35e3651988b7720f1c114fb0b7de30",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Investors need to pay close attention to DHR stock based on the movements in the options market lately.",
                "category": "company",
                "datetime": 1784057940,
                "headline": "Implied Volatility Surging for Danaher Stock Options"
              },
              {
                "id": 140898283,
                "url": "https://finnhub.io/api/news?id=39537e6385a0d8bb861f77ea8b66cc195721e4d593c7fb9cbf265322e26f00f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1784037609,
                "headline": "Danaher (DHR) Reports Next Week: Wall Street Expects Earnings Growth"
              },
              {
                "id": 140885927,
                "url": "https://finnhub.io/api/news?id=476107059e36c9c3bd928f695f98309b2a569c0900ceea5cf136c1d6443a5d58",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "EMERYVILLE, Calif., July 13, 2026--OmniAb, Inc. (NASDAQ:OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, announces that it has appointed Amechi Nwachuku to the newly-created position of Executive Vice President and Chief Operating Officer, effective today. Mr. Nwachuku will be primarily responsible for managing the strategy, operations and commercial maximization of xPloration®, OmniAb’s proprietary, innovative high-throughp",
                "category": "company",
                "datetime": 1783944000,
                "headline": "OmniAb Names Amechi Nwachuku Chief Operating Officer"
              },
              {
                "id": 140884468,
                "url": "https://finnhub.io/api/news?id=45184e5757470f427e79bf23117b6bc48aeeeb57106b73f9cf57bdd78eae7f2e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "The cell isolation market is projected to grow from USD 4.39 billion in 2026 to USD 7.97 billion by 2031, with a CAGR of 12.7%. Key drivers include the expansion of cell and gene therapy, rising demand for immune cell isolation, and increased adoption of automated systems. Techniques like centrifugation, magnetic and fluorescence-activated cell sorting, and microfluidics enable enrichment of immune, stem, and tumor cells. The consumables segment is set to lead growth, propelled by the recurring",
                "category": "company",
                "datetime": 1783931460,
                "headline": "Cell Isolation Market/Cell Separation Market by Product, Cell Type, Source, Technique, Application, End User, Competition, Region - Global Forecast to 2031"
              },
              {
                "id": 140875597,
                "url": "https://finnhub.io/api/news?id=58dd51c165523cf6f8fdca73ce8120ffc91320b6d1f05d38c15fc981bb3749aa",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359132436/image_1359132436.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DHR",
                "summary": "Mar Vista's U.S. Quality Premier strategy returned +10.15% net-of-fees in the second quarter of 2026. Read more here.",
                "category": "company",
                "datetime": 1783827720,
                "headline": "Mar Vista U.S. Quality Premier Portfolio Q2 2026 Portfolio Activity"
              },
              {
                "id": 140865222,
                "url": "https://finnhub.io/api/news?id=791ae73bf704bfbce3afcab86b035b2ad22dfe971fad0cee9e12627a57b6f74f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Abbott and Danaher both reported Q1 2026 results, but the businesses underneath those numbers point in opposite directions, and choosing the wrong one right now costs more than just a few percentage points of return.",
                "category": "company",
                "datetime": 1783707528,
                "headline": "Abbott Labs Vs. Danaher: Abbott’s Everyday Products Beat Danaher’s Slumping Biotech Equipment"
              },
              {
                "id": 140865989,
                "url": "https://finnhub.io/api/news?id=a2bb7068a7576da4a046247821b7c15e54246887626307f6b44f664fdee94d74",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2172795839/image_2172795839.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DHR",
                "summary": "Danaher stock analysis: Q1 results, bioprocessing growth, diagnostics weakness, and valuation vs. intrinsic value ($172.91). Click here to read more on DHR.",
                "category": "company",
                "datetime": 1783705485,
                "headline": "Danaher Is Getting Better, But The Stock Still Isn't Cheap"
              },
              {
                "id": 140861706,
                "url": "https://finnhub.io/api/news?id=66472b36404afa1792980621e16af98a26fb1e993b5fd7ba277342d1b73f2930",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher Corporation (NYSE:DHR) was among the stocks Jim Cramer discussed during Mad Money, as he called the growing wave of stock offerings and debt issuance a threat to the bull market. Expressing their wish to diversify, a caller inquired about the stock, and Cramer commented: Danaher’s been a huge disappointment, and we managed to get […]",
                "category": "company",
                "datetime": 1783684881,
                "headline": "Jim Cramer on Danaher: “I Don’t Want You Anywhere Near That One”"
              },
              {
                "id": 140862185,
                "url": "https://finnhub.io/api/news?id=f8bdbe29d024ca3200bbe0ad8788d4f26000e658dc3fc3853e4551ce1e85cf45",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/10/Kaufbeuren--Germany---May-2--2021-Qiagen.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "DHR",
                "summary": "Private equity giants circle Qiagen (QGEN) with potential bids of $50/share. Get the details on the molecular diagnostics buyout.",
                "category": "company",
                "datetime": 1783675567,
                "headline": "Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover"
              },
              {
                "id": 140855851,
                "url": "https://finnhub.io/api/news?id=b78669addd9952e167ffd9d6b31c6133d81abcc3fe4ed720c2df88269166eb12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Beckman Coulter Diagnostics, part of Danaher (DHR), has received CE Mark under IVDR for its Access p-Tau217 blood assay, drawing fresh attention to the stock’s diagnostics exposure and valuation. See our latest analysis for Danaher. Against this diagnostic milestone, Danaher’s share price has softened this year. The stock is at $190.77 with a year to date share price return down 17.2%, while the 1 year total shareholder return is down 4.37%. This suggests sentiment has cooled despite interest...",
                "category": "company",
                "datetime": 1783631754,
                "headline": "Danaher (DHR) Wins CE Mark For Access P Tau217 Assay, Is The Stock A Bargain?"
              },
              {
                "id": 140853716,
                "url": "https://finnhub.io/api/news?id=695956b2ab65d68b2b3f676f04a52105e2ab3b5e4a376e3960caa4fd0dc70c9b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "VTRS vs. DHR: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1783611604,
                "headline": "VTRS or DHR: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 140851723,
                "url": "https://finnhub.io/api/news?id=adab0e54b2cd05edff59575e88d1eecd33a73d0980c3a0ffdfab4fcc4e7eb226",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1442797246/image_1442797246.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DHR",
                "summary": "Illumina dominates genomics sequencing with recurring growth, NovaSeq X catalysts, and improving margins/FCF. Click to know why the ILMN shares look promising.",
                "category": "company",
                "datetime": 1783595255,
                "headline": "Illumina: While You Chased AI, This Healthcare Stock Built A $30B Moat"
              },
              {
                "id": 140849347,
                "url": "https://finnhub.io/api/news?id=d244267842f3e29e0839f9937e0151192287b6a3300b43ce4bdf512a222f1bda",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.",
                "category": "company",
                "datetime": 1783590540,
                "headline": "1 Cash-Producing Stock with Competitive Advantages and 2 We Brush Off"
              },
              {
                "id": 140843493,
                "url": "https://finnhub.io/api/news?id=6965288a4937947801c099381791136a3fc20a3c219a24c1ece262f5eee177a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher's Biotechnology segment posts 7% core revenue growth as bioprocessing demand strengthened, even as weaker product demand created headwinds.",
                "category": "company",
                "datetime": 1783525800,
                "headline": "Will Strength in Biotechnology Unit Continue to Drive DHR's Growth?"
              },
              {
                "id": 140845008,
                "url": "https://finnhub.io/api/news?id=4a277941766a5de0378493dafe626ec2f71fa68672a90db59eec27da35febbda",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "DHR",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1783517708,
                "headline": "9 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 140831580,
                "url": "https://finnhub.io/api/news?id=879c25f895af976f7a3758247d6e089b7069e8809338515280184e9028298a58",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Tap these five stocks, W, DHR, ISRG, BEAT and CSW, with rising P/E ratios to try out an out-of-the-box approach.",
                "category": "company",
                "datetime": 1783430760,
                "headline": "Bet On These 5 Top-Ranked Stocks With Increasing P/E Ratios"
              },
              {
                "id": 140827764,
                "url": "https://finnhub.io/api/news?id=4a036a29e28f8e7e681b302b197a3995519ab166928930648d83ce16b202cb4b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Beckman Coulter Diagnostics, a global leader in clinical diagnostics and a Danaher company, today announced it received CE Mark under IVDR for its Access p-Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms of cognitive decline. The company also introduced its high-specificity Access BD-pTau217 Research Use Only (RUO) assay at the Alzheimer's Association International Conference (AAIC) 2026 in London.",
                "category": "company",
                "datetime": 1783407600,
                "headline": "Beckman Coulter Diagnostics Expands Alzheimer's Portfolio with CE-Marked p-Tau217 Blood Test and New High-Specificity Research Assay"
              },
              {
                "id": 140822681,
                "url": "https://finnhub.io/api/news?id=22a6ea77688d8c8b105dd77cc1ff48d0bd4bf9db171a72f5b2c5ffc98f879259",
                "image": "",
                "source": "Benzinga",
                "related": "DHR",
                "summary": "Evercore ISI Group  analyst Vijay Kumar   maintains Danaher (NYSE:DHR) with a Outperform and lowers the price target from $232 to $230.",
                "category": "company",
                "datetime": 1783339708,
                "headline": "Evercore ISI Group Maintains Outperform on Danaher, Lowers Price Target to $230"
              },
              {
                "id": 140801152,
                "url": "https://finnhub.io/api/news?id=5102acf48264aad2443d7f7b7a501fd11da8b3cc4d6f7ce2c7464ec49961bcdc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher will release its second-quarter earnings later this month, and analysts anticipate a low single-digit bottom-line growth.",
                "category": "company",
                "datetime": 1783076083,
                "headline": "What to Expect From Danaher's Next Quarterly Earnings Report"
              },
              {
                "id": 140761657,
                "url": "https://finnhub.io/api/news?id=c083ffa01e134543722c1abb0d77239bd81b20a0bf56cb1c584d4d1e39ce65f0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "The Danaher Foundation, supported by Danaher Corporation (NYSE: DHR), today announced a $1 million commitment to support urgent, on-the-ground response to the Ebola Bundibugyo outbreak in the Democratic Republic of Congo (DRC) and Uganda through Save the Children, the International Rescue Committee (IRC) and the World Food Program USA in support of the World Food Programme (WFP).",
                "category": "company",
                "datetime": 1782736200,
                "headline": "Danaher Foundation Commits $1 Million to Ebola Outbreak Relief Efforts in Central Africa"
              },
              {
                "id": 140760377,
                "url": "https://finnhub.io/api/news?id=346aaa178a9d6d68eb59e178bd3d354cbd601a116988c339acee1699ac6959b9",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210929707/image_1210929707.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DHR",
                "summary": "Danaher (DHR) is a high-quality life sciences holding company, but current valuation does not justify a buy.",
                "category": "company",
                "datetime": 1782713054,
                "headline": "Danaher: Why I'm Not Paying 24x P/E For 8% EPS Growth"
              },
              {
                "id": 140759241,
                "url": "https://finnhub.io/api/news?id=b602e614b8580e2d1ec5496977143b7a973740f07448a6606ae6e9f4d71bd55f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher Corporation (NYSE:DHR) is one of the best long term stocks to buy according to hedge funds. On June 10, Danaher completed its acquisition of Masimo Corporation, a specialist in pulse oximetry and patient monitoring solutions. Masimo will now function as a standalone operating company within Danaher’s Diagnostics segment, retaining its original brand identity while […]",
                "category": "company",
                "datetime": 1782710880,
                "headline": "Danaher (DHR) Completes $9.9B Acquisition of Masimo Corporation"
              },
              {
                "id": 140755141,
                "url": "https://finnhub.io/api/news?id=7a050cdbff0ec4b9a349b854e3b63082db6292c5e2a10ebc247b6478b6429e8e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher Corporation (NYSE:DHR) is one of the best non-tech stocks to buy according to analysts. Masimo, Danaher Corporation’s (NYSE:DHR) specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, announced on June 22, FDA 510(k) clearance for an opioid-induced respiratory depression detection capability integrated into the Radius VSM® wearable continuous patient monitor. Supported […]",
                "category": "company",
                "datetime": 1782665159,
                "headline": "Is Danaher (DHR) One of the Best Non-Tech Stocks to Buy According to Analysts?"
              },
              {
                "id": 140736793,
                "url": "https://finnhub.io/api/news?id=1324b09288628a00abb03aa14fca83b7f7d03c6658c7e741364892aa2ac7b62e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "If you hold shares in the specialty glass and ceramics maker, you are already carrying exposure to a remarkably wide range of potential outcomes priced by the options market.",
                "category": "company",
                "datetime": 1782489081,
                "headline": "Just How Far Could Corning Stock Swing From Here?"
              },
              {
                "id": 140734645,
                "url": "https://finnhub.io/api/news?id=7b7eba6d5a30445eb9126b3327d1e1447c720452abc71bb1c4a28c3c4766c0ec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.",
                "category": "company",
                "datetime": 1782470905,
                "headline": "3 Mid-Cap Stocks Walking a Fine Line"
              },
              {
                "id": 140730466,
                "url": "https://finnhub.io/api/news?id=ce4508fdc2f598b787c33fa54b2dd32d4a925f6c47827664cbd6b5ae5b6fb4be",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Shares of diversified science and technology company Danaher (NYSE:DHR) jumped 2.8% in the morning session after its recently acquired subsidiary, Masimo, received U.S. Food and Drug Administration (FDA) clearance for an artificial intelligence-enabled feature on its wearable patient monitoring platform.",
                "category": "company",
                "datetime": 1782427310,
                "headline": "Danaher (DHR) Stock Is Up, What You Need To Know"
              },
              {
                "id": 140729515,
                "url": "https://finnhub.io/api/news?id=84dbeff0488515ad3bab64536291eea3fc0ca4a82cb20f3f215d7c73069f1e7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "On June 25, 2026, investors tracked deal progress as Bio-Techne shares responded to the proposed buyout terms.",
                "category": "company",
                "datetime": 1782423822,
                "headline": "Stock Market Today, June 25: Bio-Techne Surges After Merck KGaA Announces $73-Per-Share Cash Acquisition Offer"
              },
              {
                "id": 140728493,
                "url": "https://finnhub.io/api/news?id=b7a657f92deb5cbc96369a2645a254c397418efdbb34bbae85050b9072793181",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "If you are wondering whether Danaher at around US$188.87 is starting to look attractive again, the stock's valuation metrics offer some clear signals that are worth unpacking. Over the very short term, Danaher has risen 6.2% over the last 7 days and 9.8% over the last 30 days, even though the stock is still down 18.0% year to date and has declined 5.4% over the past year. These moves sit against a backdrop where investors have been reassessing large healthcare and life sciences stocks, with...",
                "category": "company",
                "datetime": 1782414477,
                "headline": "Danaher (DHR) Stock Weighs Mixed Valuation Signals After Recent Price Rebound"
              },
              {
                "id": 140727473,
                "url": "https://finnhub.io/api/news?id=25032d1a4c79991a8b7630fb6aef2ecb9846bef633b005ab095e28bc4fac9b79",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Bioprocess Digital Twin Market size & share revenue was valued at approximately USD 0.89 Billion in 2025 and is expected to reach USD 1.08 Billion in 2026 and is expected to reach around USD 6.47 Billion by 2035, at a CAGR of 19.6% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Siemens AG (SIMATIC Biopr",
                "category": "company",
                "datetime": 1782408600,
                "headline": "[Latest] Global Bioprocess Digital Twin Market Size/Share Worth USD 6.47 Billion by 2035 at a 19.6% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)"
              },
              {
                "id": 140727474,
                "url": "https://finnhub.io/api/news?id=596ab5ef675c2090c2f5131bb75b67902625cce5035075dcb476ff79fde45d36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "NEW YORK, June 25, 2026--Eckuity Capital, a North American healthcare growth equity firm, today announced the first close of Eckuity Capital Fund II and the fund’s inaugural investment, leading the Series C of Automata Technologies alongside Danaher, a global science and technology leader.",
                "category": "company",
                "datetime": 1782405900,
                "headline": "Eckuity Capital Launches Fund II and Backs Automata Technologies"
              },
              {
                "id": 140725817,
                "url": "https://finnhub.io/api/news?id=99817ea5c35e56b67d91017b2818d0607a873f9bb9c264f3cf707be8f769990f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Should investors be excited or worried when a stock crosses above the 20-day simple moving average?",
                "category": "company",
                "datetime": 1782394503,
                "headline": "Danaher (DHR) Crossed Above the 20-Day Moving Average: What That Means for Investors"
              },
              {
                "id": 140723949,
                "url": "https://finnhub.io/api/news?id=d2677b2d8b96dbcb42b1cc6213f453f5d03b8dbd6f7add01322411980e68b907",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have realized strong financial performance, and over the past six months, the industry’s 7.6% return has closely followed the S&P 500.",
                "category": "company",
                "datetime": 1782384590,
                "headline": "3 Healthcare Stocks with Questionable Fundamentals"
              },
              {
                "id": 140721364,
                "url": "https://finnhub.io/api/news?id=4b5aadfbcc257d7b75728877c7928c1fcda9e14dff348e7708b900e7b1ca433e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "On 22 June 2026, Masimo, a Danaher company, received FDA 510(k) clearance for an AI-enabled opioid-induced respiratory depression detection feature integrated into its Radius VSM wearable continuous patient monitor. This clearance highlights how Danaher is pushing pulse oximetry beyond basic vital sign tracking toward AI-driven, clinically actionable insights in hospital monitoring. Next, we’ll examine how integrating AI-based opioid-induced respiratory depression detection into Radius VSM...",
                "category": "company",
                "datetime": 1782357368,
                "headline": "Is Danaher (DHR) Using Masimo’s New FDA-Cleared AI Tool To Redefine Its Medtech Edge?"
              },
              {
                "id": 140717096,
                "url": "https://finnhub.io/api/news?id=94b7d0bff663500e008b569194f7c24b2393b2c6331878775fce6236aef3dfc1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Laboratory Equipment Services Market size & share revenue was valued at approximately USD 28.94 Billion in 2025 and is expected to reach USD 31.47 Billion in 2026 and is expected to reach around USD 62.83 Billion by 2035, at a CAGR of 8% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Thermo Fisher Scien",
                "category": "company",
                "datetime": 1782329400,
                "headline": "Global Laboratory Equipment Services Market Size/Share Worth USD 62.83 Billion by 2035 at a 8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)"
              },
              {
                "id": 140715611,
                "url": "https://finnhub.io/api/news?id=96a50a2534ce8478dfbae223c511c26069b212f5480dcdbe4f3f3e376d418102",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "The life sciences giant is transforming its diagnostics segment with its acquisition of Masimo Corporation, shifting from traditional laboratory testing into patient-connected, real-time data streams.",
                "category": "company",
                "datetime": 1782323700,
                "headline": "Danaher Is Down 22% This Year. Is the Masimo Acquisition the Entry Point Investors Have Been Waiting for?"
              },
              {
                "id": 140712982,
                "url": "https://finnhub.io/api/news?id=88a890a854d8b6b7e724bc472b1e109220e28b592929e24b3601d61bc148f2aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher Corporation (NYSE:DHR) is one of the top high-conviction stocks to buy according to hedge funds. HSBC cut the price target on Danaher Corporation (NYSE:DHR) to $230 from $270 on June 3 and maintained a Buy rating on the shares. The firm told investors in a research note that market expectations on life science tools […]",
                "category": "company",
                "datetime": 1782303296,
                "headline": "HSBC Cuts PT on Danaher Corporation (DHR) – Here’s Why"
              },
              {
                "id": 140704361,
                "url": "https://finnhub.io/api/news?id=b0b5341d803cbe8a4216da13a504d4cf7f8b7a6282ec12ec2818aa6d37f8413e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "VTRS vs. DHR: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1782229205,
                "headline": "VTRS vs. DHR: Which Stock Is the Better Value Option?"
              },
              {
                "id": 140699780,
                "url": "https://finnhub.io/api/news?id=dd1112f1aff8f825ebca7a0e92bdc92ea99ce0a6b562493e7a674f9dbafc92e8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.",
                "category": "company",
                "datetime": 1782201166,
                "headline": "1 Profitable Stock with Promising Prospects and 2 That Underwhelm"
              },
              {
                "id": 140696238,
                "url": "https://finnhub.io/api/news?id=0882ec675d4988a27009cfa1353e6d81971628d6cea00e0677f96c907d008191",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "This industrial powerhouse is firing on all cylinders, but it might be adding more of the same risk you already own.",
                "category": "company",
                "datetime": 1782159707,
                "headline": "Is AMETEK Stock Just More Market Exposure?"
              },
              {
                "id": 140696250,
                "url": "https://finnhub.io/api/news?id=024717471b25b12fa2f2da1bcac1d54b321ced925dd3f835c0ad205d0806da20",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2026 on Tuesday, July 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations.",
                "category": "company",
                "datetime": 1782159300,
                "headline": "Danaher Schedules Second Quarter 2026 Earnings Conference Call"
              },
              {
                "id": 140691732,
                "url": "https://finnhub.io/api/news?id=3d42893fd01bb01cf90ea6c6a827dc78c94cd364ca1c36f538a2d5cb9d9980f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "IRVINE, Calif., June 22, 2026--Masimo smartSET™-powered, AI-enabled OIRD detection has received FDA 510(k) clearance for the Radius VSM® wearable continuous patient monitor.",
                "category": "company",
                "datetime": 1782129600,
                "headline": "Masimo Receives FDA 510(k) Clearance for AI-Enabled Opioid-Induced Respiratory Depression (OIRD) Detection on Radius VSM® to Help Identify Respiratory Risk Sooner"
              },
              {
                "id": 140696362,
                "url": "https://finnhub.io/api/news?id=ee5e349c2a891c516667ef5a0da777c5f6a2f874999864b3a19f00035a0454f9",
                "image": "",
                "source": "Benzinga",
                "related": "DHR",
                "summary": "Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, today announced FDA 510(k) clearance for an opioid-induced respiratory depression",
                "category": "company",
                "datetime": 1782115619,
                "headline": "Masimo Receives FDA Clearance For Opioid-Induced Respiratory Depression Detection Capability Combined Into Its Radius VSM"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 3,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.9,
            "source_article_count": 62,
            "discarded_article_count": 44
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.2,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 0.9,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.9,
            "vcp_reason": "站上MA50；升放量(近10日2日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 4186796.6666666665,
              "down_days": 3,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 3769940,
              "avg_vol_20": 4308625,
              "avg_vol_30": 4186796.6666666665,
              "range_pct_10": 0.0835860971607578,
              "range_pct_20": 0.16095669036845509,
              "range_pct_30": 0.16095669036845509,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.90043541641621,
              "dist_to_20d_high": 0.026525969311196038,
              "down_shrink_days": 1,
              "breakout_level_20d": 206.59,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.5193080012357121
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "優秀",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.4375217542638357,
              "turnoverUsdM": 1222.9006380500002,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.8,
          "stopLevels": {
            "symbol": "US.DHR",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 191.3058,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 3,
              "macd_score": 3,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.7,
            "stop_loss_percent": 4.9,
            "take_profit_price": 218.0059,
            "target_multiplier": 2.2,
            "technical_strength": 2.35,
            "take_profit_percent": 8.4
          },
          "positionPoints": 1.8,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.7230615450521207,
          "stopLossPercent": 4.875043508527671,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 100,
    "atr": {
      "atr": 4.9021,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.44
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "強勢區",
      "score": 10,
      "value": 98.39
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1827
    },
    "kdj": {
      "d": 81.6,
      "j": 75.56,
      "k": 79.59,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 62.81
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 6,
      "trend": "有流入",
      "value": 17573945,
      "recentSlope": 39314.5,
      "previousSlope": 2212060
    },
    "rsi": 60.84,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 195.3847,
      "position": "SAR喺價下",
      "distancePct": 2.85,
      "previousTrend": "上升"
    },
    "ma50": 183.2274,
    "macd": {
      "macd": 5.422186420753178,
      "trend": "強烈看漲",
      "signal": 5.0069803495194645,
      "histogram": 0.41520607123371356
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 194.5922,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 18
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.43,
      "score": 6,
      "avgVolume": 4249738,
      "currentVolume": 6080755
    },
    "derived": {
      "ma20": 194.695,
      "ma50": 183.2274,
      "prevClose": 203.83,
      "avgVolume10": 3911636,
      "avgVolume20": 4249738,
      "changePercent": -1.33,
      "avgVolumeForScore": 4249738
    },
    "ma_cross": {
      "ma20": 194.695,
      "ma50": 183.2274,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 193.498,
      "prevMa50": 182.7036,
      "spreadPct": 6.26,
      "isVolumeBreakout": true
    },
    "bollinger": {
      "lower": 180.9449,
      "upper": 208.4451,
      "position": "上半部"
    },
    "rsi_short": 58.53,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.43
    }
  }
}

{
  "close": 201.11,
  "volume": 6080755,
  "changePercent": -1.33
}